Pfizer inks strategic collaboration with Syapse to analyze RWD, advance outcomes research
Syapse’s insights platform, data sharing network, and industry partnerships help advance the delivery of precision cancer care, according to the company, which today announced a strategic collaboration with Pfizer.
“With its health system partners, Syapse has built a network of real-world data that offers a unique view of modern cancer care, including how molecular tests are used to diagnose and treat patients. A real-world database, if you will,” a Syapse spokesperson told us.
The company’s partners include Advocate Aurora Health, CommonSpirit Health, Henry Ford Health System, Providence St. Joseph Health, and Seoul National University Hospital. Syapse also earlier this year announced a collaboration with Amgen, and in 2018 initiated a partnership with Medidata to develop a new suite of solutions addressing precision medicine challenges.
Per its strategic collaboration with Pfizer, the companies will initially focus on molecular testing and precision oncology therapy choices and outcomes of patients in the US health care system.
“Syapse will provide Pfizer with the ability to analyze this de-identified real-world data and work with them to collaboratively advance outcomes research projects,” the spokesperson added.
The deal with Syapse is Pfizer's latest through which the pharma company aims to advance oncology through the use of real-world data. Pfizer in April of this year announced a partnership with Concerto HealthAI to accelerate actionable insights for Pfizer’s precision oncology work on investigational and commercialized therapeutics for the treatment of solid tumors and hematologic malignancies.
